Cargando…

Soluble Isoform of Suppression of Tumorigenicity 2 (ST2) Biomarker in a Large Cohort of Healthy Pediatric Population: Determination of Reference Intervals

Introduction: Only little data exists on ST2 reference intervals in healthy pediatric populations despite the high importance of this biomarker in adults with heart failure. The aim of the study was to assess the reference intervals of ST2 in a wide healthy pediatric cohort. Methods: We evaluated th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perrone, Marco Alfonso, Favresse, Julien, D’Alessandro, Annamaria, Albanese, Federica, De Bruyne, Coralie, Ceccarelli, Stefano, Drago, Fabrizio, Guccione, Paolo, Porzio, Ottavia, Leonardi, Benedetta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409801/ https://www.ncbi.nlm.nih.gov/pubmed/36012931 http://dx.doi.org/10.3390/jcm11164693

Ejemplares similares

Reference interval and the role of soluble suppression of tumorigenicity 2 (sST2) in subclinical cardiac dysfunction at health checkups
por: Nah, Eun‐Hee, et al.
Publicado: (2020)

Soluble Suppression of Tumorigenicity 2 and Echocardiography in Sepsis
por: Yang, Hyun Suk, et al.
Publicado: (2016)

Risk Factors of Right Ventricular Dysfunction and Adverse Cardiac Events in Patients with Repaired Tetralogy of Fallot
por: Leonardi, Benedetta, et al.
Publicado: (2021)

The Effects of Physical Inactivity and Exercise at Home in Young Patients with Congenital Heart Disease during the COVID-19 Pandemic
por: Gentili, Federica, et al.
Publicado: (2021)

Reference Intervals for Coagulation Parameters in Developmental Hemostasis from Infancy to Adolescence
por: Di Felice, Giovina, et al.
Publicado: (2022)

Diagnostic Value of Soluble Suppression of Tumorigenicity-2 for Heart Failure
por: Huang, Dong-Hui, et al.
Publicado: (2016)

Soluble suppression of tumorigenicity-2 for risk stratification in outpatients with heart failure
por: Öncel, Can Ramazan
Publicado: (2018)

Interleukin-33 and soluble suppression of tumorigenicity 2 in scleroderma cardiac involvement
por: Iannazzo, Francesco, et al.
Publicado: (2022)

Prognostic role of soluble suppression of tumorigenicity-2 on cardiovascular mortality in outpatients with heart failure
por: Gül, İbrahim, et al.
Publicado: (2017)

Soluble suppression of tumorigenicity 2 as outcome predictor after cardiopulmonary resuscitation: an observational prospective study
por: Rezar, Richard, et al.
Publicado: (2021)

Soluble Suppression of Tumorigenicity-2 Associates With Ventilator Dependence in Coronavirus Disease 2019 Respiratory Failure
por: Alladina, Jehan W., et al.
Publicado: (2021)

Soluble suppression of tumorigenicity 2 associated with fulminant myocarditis in children: A retrospective observational study
por: Hou, Wenquan, et al.
Publicado: (2023)

Soluble suppression of tumorigenicity 2 is a potential predictor of post-liver transplant renal outcomes
por: Moon, Jong Joo, et al.
Publicado: (2023)

Soluble Suppression of Tumorigenicity-2 as a Candidate Prognostic Marker for Stroke: A Systematic Review
por: Ahmadzadeh, Koohyar, et al.
Publicado: (2023)

A meta-analysis of soluble suppression of tumorigenicity 2 (sST2) and clinical outcomes in pulmonary hypertension
por: Luk, King Sum, et al.
Publicado: (2017)

Serum soluble suppression of tumorigenicity 2 as a novel inflammatory marker predicts the severity of acute pancreatitis
por: Zhang, Yan, et al.
Publicado: (2021)

Prognostic Value of Soluble Suppression of Tumorigenicity 2 in Chronic Kidney Disease Patients: A Meta-Analysis
por: Guo, Guangying, et al.
Publicado: (2021)

Circulating Soluble Suppression of Tumorigenicity 2 Predicts Recurrence After Radiofrequency Ablation of Persistent Atrial Fibrillation
por: Tan, Ruopeng, et al.
Publicado: (2021)

Soluble suppression of tumorigenicity 2 associated with atrial fibrillation detected after stroke: A retrospective study
por: Hou, Wenquan, et al.
Publicado: (2023)

Isoform switch of CD44 induces different chemotactic and tumorigenic ability in gallbladder cancer
por: Miwa, Takeshi, et al.
Publicado: (2017)

Isoform-specific promotion of breast cancer tumorigenicity by TBX3 involves induction of angiogenesis
por: Krstic, Milica, et al.
Publicado: (2019)

Cerebrospinal Fluid Levels of AFP and hCG: Validation of the Analytical Method and Application in the Diagnosis of Central Nervous System Germ Cell Tumors
por: D’Alessandro, Annamaria, et al.
Publicado: (2021)

Study of the Association between Thiols and Oxidative Stress Markers in Children with Obesity
por: D’Alessandro, Annamaria, et al.
Publicado: (2022)

Prognostic Utility of Soluble Suppression of Tumorigenicity 2 level as a Predictor of Clinical Outcomes in Incident Hemodialysis Patients
por: Seo, Suk Min, et al.
Publicado: (2018)

Soluble Suppression of Tumorigenicity 2 is Directly Correlated with Glycated Hemoglobin in Individuals with an Average glycemia in the Normal/Prediabetes Range
por: Hasan, Amal, et al.
Publicado: (2020)

Elevated Soluble Suppressor of Tumorigenicity 2 Predict Hospital Admissions Due to Major Adverse Cardiovascular Events (MACE)
por: Chen, Dongqing, et al.
Publicado: (2023)

Value of increased soluble suppressor tumorigenicity biomarker 2 (sST2) on admission as an indicator of severity in patients with COVID-19
por: Arnaldos-Carrillo, María, et al.
Publicado: (2023)

EGFR Soluble Isoforms and Their Transcripts Are Expressed in Meningiomas
por: Guillaudeau, Angélique, et al.
Publicado: (2012)

Differential and Predictive Value of Galectin-3 and Soluble Suppression of Tumorigenicity-2 (sST2) in Heart Failure with Preserved Ejection Fraction
por: Cui, Yameng, et al.
Publicado: (2018)

Contemporary Risk Stratification After Myocardial Infarction in the Community: Performance of Scores and Incremental Value of Soluble Suppression of Tumorigenicity‐2
por: Gerber, Yariv, et al.
Publicado: (2017)

Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab
por: Magro, Fernando, et al.
Publicado: (2019)

Multi-marker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis
por: Kim, Hanah, et al.
Publicado: (2017)

Serum soluble suppression of tumorigenicity-2 level associates with severity of pulmonary hypertension associated with uncorrected atrial septal defect
por: Pratama, Reza S., et al.
Publicado: (2020)

The soluble suppression of tumorigenicity 2 as a biomarker of early cardiac remodeling in bradycardia patients receiving permanent pacemaker therapy
por: Iqbal, Mohammad, et al.
Publicado: (2023)

TREM2 splice isoforms generate soluble TREM2 species that disrupt long-term potentiation
por: Moutinho, Miguel, et al.
Publicado: (2023)

The Effects of Exercise Training on Cardiopulmonary Exercise Testing and Cardiac Biomarkers in Adult Patients with Hypoplastic Left Heart Syndrome and Fontan Circulation
por: Perrone, Marco Alfonso, et al.
Publicado: (2022)

TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions
por: Shirole, Nitin H, et al.
Publicado: (2016)

The pro-inflammatory marker soluble suppression of tumorigenicity-2 (ST2) is reduced especially in diabetic morbidly obese patients undergoing bariatric surgery
por: Demyanets, Svitlana, et al.
Publicado: (2020)

Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy
por: Kieler, Markus, et al.
Publicado: (2018)

The association between soluble suppression of tumorigenicity-2 and long-term prognosis in patients with coronary artery disease: A meta-analysis
por: Liu, Niannian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fqkipe3fl5t5bf4g2n9g6tirn6